Literature DB >> 3122973

How far does prophylaxis against infection in total joint replacement offset its cost?

U Persson1, F Montgomery, A Carlsson, B Lindgren, L Ahnfelt.   

Abstract

Selection of a cost effective method of prophylaxis against infection for patients undergoing total joint replacement was shown to depend on the number of arthroplasties performed each year at individual hospitals. When 100 arthroplasties were performed each year the prophylactic use of systemic antibiotics minimised the total costs of the department--that is, the combined costs of prophylaxis and reoperation for deep sepsis. Some departments also used local antibiotic prophylaxis in the form of polymethylmethacrylate cement impregnated with gentamicin or a combination of systemic and local prophylaxis at almost as low a total cost and with comparable effect. Selection of a method of prophylaxis should not be determined solely on the basis of reducing costs. When a value was assigned to the effects of loss of health an economic optimum was established that allowed selection of a more costly method of prophylaxis together with further reductions in the incidence of infection and the need for reoperation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3122973      PMCID: PMC2544707          DOI: 10.1136/bmj.296.6615.99

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  3 in total

1.  The cost implications of clean air systems and antibiotic prophylaxis in operations for total joint replacement.

Authors:  O M Lidwell
Journal:  Infect Control       Date:  1984-01

2.  [Operating box or antibiotic prophylaxis? A comparison of costs].

Authors:  L Borgquist; L Lidgren; L Lindberg
Journal:  Lakartidningen       Date:  1978-04-26

3.  Systemic antibiotics and gentamicin-containing bone cement in the prophylaxis of postoperative infections in total hip arthroplasty.

Authors:  G Josefsson; L Lindberg; B Wiklander
Journal:  Clin Orthop Relat Res       Date:  1981-09       Impact factor: 4.176

  3 in total
  4 in total

Review 1.  Economic evaluation of pharmaceuticals: a European perspective.

Authors:  M Drummond; F Rutten; A Brenna; C G Pinto; B Horisberger; B Jönsson; C Le Pen; J Rovira; M G von der Schulenburg; H Sintonen
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

2.  Therapeutic conservatism: more costly in the long term? A UK perspective.

Authors:  J P Griffin
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

3.  Economical analysis on prophylaxis, diagnosis, and treatment of periprosthetic infections.

Authors:  Mariano Fernandez-Fairen; Ana Torres; Ann Menzie; Daniel Hernandez-Vaquero; José Manuel Fernandez-Carreira; Antonio Murcia-Mazon; Enrique Guerado; Luis Merzthal
Journal:  Open Orthop J       Date:  2013-06-14

4.  Economics and preventing hospital-acquired infection.

Authors:  Nicholas Graves
Journal:  Emerg Infect Dis       Date:  2004-04       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.